報價延遲最少15分鐘:2025/07/18 17:46 EDT
盤後時段
|
||||
|
2.55 
|
|
|
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.17/-1.69
|
|
企業價值
22.88M
|
| 資產負債 |
|
每股賬面淨值
-1.08
|
| 現金流量 |
|
現金流量率
0.31
|
| 損益表 |
|
收益
9.78K
|
|
每股收益
--
|
|
同行比較
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
報價延遲最少15分鐘：2025/07/18 17:46 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Dare Bioscience Inc is a biopharmaceutical company committed to advancing products for women's health. The company identifies, develops, and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatmentof bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health. |
